Weekly Digest – May 2026 Weekly Digest – May 2026 22 May 2026: Datroway approved in the U.S. as first TROP2-directed ADC for 1L metastatic TNBC patients ineligible for PD-1/PD-L1 inhibitors AstraZeneca and Daiichi Sankyo have secured U.S. FDA approval […]
Weekly Digest – May 2026 Weekly Digest – May 2026 15 May 2026: ENHERTU approved in the US for two new indications for patients with HER2-positive early Breast cancer ENHERTU received two new U.S. FDA approvals in HER2-positive early breast […]
Weekly Digest – May 2026 Weekly Digest – May 2026 21 May 2026: CDSCO approves Astellas’ PADCEV for first-line advanced Bladder cancer treatment Astellas Pharma’s PADCEV has been approved by CDSCO for first-line treatment of locally advanced or metastatic urothelial […]
